Vital Signs qxp by jolinmilioncherie


									   Healthcare & Life Sciences
   Vital Signs
            Strategic Insights for Healthcare Executives

                                                                                                                                   May 1, 2006

This Week's Industry Focus:
Medical Devices
   First Rate Healthcare in Third World Countries: How Medical Tourism is Altering the
   Face of Competition in the Healthcare Industry
   Author:Venkat Rajan

 In the 1980s blue collar workers on assembly lines manufacturing electronic goods, cars and clothing saw their jobs sent overseas to
 countries in Latin America and the Pacific Rim. In the mid to late 1990s high school educated workers saw their call center and clerical
 jobs sent to nations across the Pacific such as India, followed by college educated engineers and programmers witnessing their complex
 assignments outsourced to cheaper educated labor abroad. Could the next stage really be middle class Americans entrusting their
 healthcare needs to doctors and health care providers located halfway across the globe?

 As healthcare costs continue to spiral, and insurance payers begin to curtail reimbursement payments for non-life threatening ailments and
 procedures deemed "experimental", it is conceivable that more and more Americans will turn to foreign hospitals for their medical needs.
 The most commonly cited instigator for growth in the U.S. health care industry has always been the rise of the baby boomer population;
 but if those patients are turning to international health care providers there arises a significant level of uncertainty as to what the residual
 impact on the industry as a whole will be. Healthcare competition on a global scale means increased patient demand will not necessarily
 directly translate to a corresponding number of imaging and diagnostic procedures performed, devices sold, or hospital beds occupied in
 the United States.

 Coming Back a New Man

 Vacationing abroad is often a means to relax and alleviate one's mental stress, but now Americans are coming back with new knees, facelifts,
 and even heart valves.The practice has gained the moniker "Medical Tourism", because patients can afford to add the price of a flight, hotel,
 and a two week vacation on to the cost of the medical procedure and still only pay a fraction of what they would in the U.S.

 James Spark, a 59 year old American embodies the spirit of adventure and vigor that distinguishes the current baby boomer population
 from any previous generation of Americans over the age of 60. James Spark was forced to turn to foreign medical providers when it came
 to restoring his health due to costs and time.What years of mountain climbing in the Rockies, Andes, and Himalayas ravaged on his knees
 and shoulders, James was able to correct in India for a fraction of the cost in the United States. Surgical procedures to reconstruct his
 anterior cruciate ligament (ACL) and the torn ligaments in his shoulder that would have totaled nearly $38,000 in out of pocket expenses
 cost him a mere $6,000 USD equivalent in India.

Learn more at:                                                       Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                            This Week's Industry Focus:
                                                                                                                                       Medical Devices

  Being able to live an active and content life is more important to aging Americans than ever before.This trend is not exclusively limited to
  middle and lower-middle class Americans without healthcare; in fact in many cases the procedures abroad are often significantly less
  expensive than even the co-pay that these individuals would have to pay for their procedures.

  Out of Pocket, Out of Country:Threatening Profitable Sectors of US Healthcare

  Profitability for healthcare providers in the United States for the future is expected to be heavily tied to the number of elective and quality
  of life procedures performed. Excessive profiteering of life threatening conditions such as heart disease or cancer requires a delicate balance
  of maximizing profit versus maintaining an altruistic health care provider corporate image so as to not be perceived as sinister or greedy.

  Corrective laser eye surgery and cosmetic procedures are already paid completely out-of-pocket by patients. Inspite of the out-of-pocket
  cost, these procedures have very high demand and some of the highest profit margins in the healthcare industry.As more Americans explore
  the most economic alternatives, the risk of losing these procedures to foreign healthcare providers increases, threatening overall device
  sales and the number of procedures performed in the U.S.

  In the U.S., device manufacturers can charge high rates for all non-elective procedures because reimbursement payers are willing to pay the
  price; while price erosion has hit standard hospital equipment and general use devices purchased through secondary group purchasing
  organizations, pricing for sophisticated life saving devices has remained fairly stable.Abroad without the existing insurance structure, device
  pricing works under different dynamics and manufactures in certain cases must concede to sell devices for the maximum price that those
  organizations are able to spend.

  Elective procedures and non-life threatening corrective procedures are essentially being squeezed out due to the mounting cost of treating
  ailments of a critical and chronic nature.An interesting paradigm shift in the pharmaceutical industry has been in relation to how cancer and
  other critical disease therapeutics are priced. No longer are they priced solely on the cost of production of the drug, but are now evaluated
  on the value to the patient. Genentech, for instance, raised the price of its lung cancer therapeutic,Tarceva, by 30 percent due to an improved
  perceived value to patients. In a recent New York Times article, Dr. Susan Desmond-Hellmann, the president of product development for
  Genentech is quoted as saying, "Tarceva was a more powerful and more active agent than what we understood at the time of launch, and
  so more valuable." If approved for
                                                                      Rising costs of healthcare drive medical tourism
  breast and lung cancer, Genentech has
  indicated it will increase the price of its
  colon cancer drug Avastin to nearly                Out-of-Pocket vs. Private Insurance for Health Services and Supplies
  $100,000, annually. Other therapeutics                                                         2003
  following a similar trajectory include           Physician and Clinical Services                       16%

  drugs like Mustargen, a cancer                                                                                               30%
                                                                     Hospital Care          7%
  therapeutic drug developed nearly 60
                                                         Dental/Other Professional             9%
  years ago, which has increased in                                                                            20%

  wholesale price in recent years by              Nursing Home/Home Health Care        3%
  nearly ten fold, along with other                                                                   14%
                                                                Prescription Drugs                                   23%
  therapeutics such as Norvir, an AIDS
                                                                    Administration 0%                 14%
  therapeutic developed by Abbott
  Laboratories, which increased in price                                      Other 1%
  from $54 to $265 a month.
                                                                            0%       5%       10%      15%      20%      25%      30%      35%

  Reimbursement payers such as                                                   Out-of-Pocket   Private Insurance

  Medicare and private payers in most                                            Blue Cross and Blue Shield Association, Medical Cost Reference Guide 2006
                                                                                                            Source: California Healthcare Foundation (2005)

Learn more at:                                                        Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                                This Week's Industry Focus:
                                                                                                                                           Medical Devices

  cases can do nothing but pay for the majority of these life saving drugs. As the costs mount, expect reimbursement payers to slash the
  amount of money they are willing to pay for non life threatening and quality of life procedures. Furthermore, we can expect these payers
  to deem more and more new procedures and devices as "experimental", increasing their observational times of these techniques. It could
  lead to longer lags between regulatory approval of a device and that device attaining full reimbursement.

  Take the case of Tracy Pierce, a fully insured 37 year old American diagnosed with kidney cancer.As the cancer was eating away at his kidneys,
  numerous doctors and physicians suggested a number of treatment options to retard the progression of the disease, every one of which
  was denied and deemed experimental by his insurance company, First-Health Coventry. As relatives and doctors continued to appeal his
  case, the cancer spread from his kidneys to his lungs and brain. Even in his final week First-Health Coventry denied him the oral morphine
  recommended to reduce his pain.Though an extreme and isolated case, more insurance providers are raising the bar as to what they deem
  necessary and proven and what is investigational and experimental.

  It is conceivable that a procedure like cardiac ablation for treating atrial fibrillation could first be performed predominantly overseas as
  insurance payers balk at payment. If enough patients report significant benefit, rather than waiting for the procedure to be approved in the
  United States it is more likely patients will be more proactive and seek out physicians in countries willing to perform the procedure.

  The types of procedures that will see the most penetration abroad will be less invasive procedures such as dental applications that still can
  cost a considerable amount of out of pocket expenses. In the U.S. a teeth whitening procedure can cost close to $600 dollars in some cases,
  and only $100 abroad. Other more expensive procedures such as performing a metal free bridge or root canal can cost close to $5,000
  and $600 in the U.S, and only $500 and $100 respectively abroad.While the cost of these simple procedures might not warrant the cost of
  a plane ticket, it is a viable option for tourists who had already planned on visiting these lower cost health care countries for leisure.Areas
  like Thailand, Malaysia, and India have luscious beach side resorts that cater exclusively to foreigners.Vacationers that had planned on taking
  an overseas trip could conceivably schedule dental procedure along with corrective laser eye procedures or other cosmetic procedures and
  warrant the savings.

  There are a number of international health care facilities comparable to Jaslok Hospital in Mumbai, India, which is equipped with the latest
  Siemens, 64-slice CT scanners, high tech flat panel Cathlabs, and state of the art MRI systems.They can perform a complete body scan for
  the price of $126, while in the U.S. a
  combination whole-body scan and virtual
  colonoscopy is currently priced between               Percent of Employers Offering Health Benefits to Employees
  $1,400 and $1,750. The average annual
  salary of a top radiologist in the U.S.
  might be $300,000, compared with                70%                            66%
  $20,000 in India. Even U.S. hospital are        60%

  investigating the use of radiologists in        50%
  foreign countries as a means to keep            40%                                                             From 2000-2005,
  costs down, creating a significant threat                                                                       premiums paid by
  to a number of radiology centers in the                                                                         employers increased
  country.                                                                                                        by 73%.

  While there is very little that a patient or     0%
                                                                2000                 2003                 2005
  reimbursement payer can do about the
  high cost of drugs with regards to
                                                                                       Blue Cross and Blue Shield Association, Medical Cost Reference Guide 2006
  international alternatives, they can save
                                                  Source: “Employer Health Benefits 2005 Annual Survey,” (#7315),The Henry J. Kaiser Family Foundation and Health
  costs when it comes to surgical                                                                                 Research and Educational Trust, September 2005

Learn more at:                                                            Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                                         This Week's Industry Focus:
                                                                                                                                                    Medical Devices

  procedures.While purchasing drugs without a prescription abroad is illegal and can be confiscated at a customs check point, there is very
  little that can be done from a governmental standpoint about someone who leaves and returns to the country after a heart valve,
  orthopedic, cosmetic, or diagnostic procedure.

  Aggressive and Coordinated Government Sanctioned Marketing

  Medical tourism is not a passing anomaly occurring through word of mouth and by happenstance. It is a foreign government sanctioned and
  aggressively pursued economic opportunity.

  A simple web engine search produces numerous informative governmental websites from nations spanning across Latin America, South Asia,
  and South Africa. They contain informative content on their best medical facilities that cater to foreigners and the types of surgeries they
  are most adept at performing. Moreover, they offer comprehensive packages that take into account flight arrangements, hotel stays, and even
  a tour guide/translator to work around language barriers.

  Latin American countries such as Costa Rica have long been a haven for cheap plastic surgery. It affords patients the opportunity for a cheap
  procedure and time to recover from surgical scars.

  The medical tourism industry in India is currently at $333 million with a projected growth rate of 25 percent according to governmental
  officials. If their slightly optimistic outlook holds true, their market should reach $2 billion dollars by 2012.That would be $2 billion dollars
  per year in India alone that is not being spent in healthcare facilities in the U.S. or Western Europe.

  In 2000 there were 150,000 medical visitors to the small yet highly affluent nation of Singapore.That number grew to 211,600 in 2002 and
  230,000 in 2003.The official Singapore Tourism board has predicted that the number of foreign nationals visiting their country for medical
  treatment will be nearly 500,000 by 2007.

                                                                                     Consumer Engagement: General Trends
  Other Asian countries actively and
  significantly pursuing medical tourists
  include the Philippines, Malaysia, and                                 Household Health Spending as a Percentage of Before-Tax-Income
  Thailand. These nations see medical                                                                2003
  tourism as a means to generate new
  investments in their own healthcare
                                                                         20%               18%
  industry, hopefully developing the
  infrastructure and resources that could                                16%
                                                     Percent of Income

  eventually benefit their own citizens, in                              12%
  addition to generating millions of dollars
  in revenues for the home grown cottage
  industries that thrive on foreign visitors.                            4%                                                                3%

  The irony of the situation currently is                                           Poorest Households                            Wealthiest Households
                                                                                     (Lowest Quintile)                              (Highest Quintile)
  the utter lack of equivalent high level
                                                                                                           Difference by Income
  healthcare available to the individual
  citizens in the majority of these nations.
  Nations such as India and Malaysia               In 2003, the poorest households spent approximately $1,400 or 18% of their before-tax-
  contain pockets of slums and rural areas             income for healthcare compared to $3,600 or 3% for the wealthiest households.
  that resemble the worst of some third
                                                                                                 Blue Cross and Blue Shield Association, Medical Cost Reference Guide 2006
                                                                                                              Source: Cowan, CA et al. (2005) Health Care Financing Review

Learn more at:                                                                      Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                          This Week's Industry Focus:
                                                                                                                                     Medical Devices

  world countries in Africa and Latin America, but also contain pockets of affluent and bustling metropolitan areas that resemble the best of
  Western Europe and the U.S. as well. Based on a buying power and education level comparable to most middle class Americans, the middle
  class in India surpasses the entire population of France. This dichotomy has created a nation home to some of the best health care facilities
  in the world too costly for the majority of their destitute native population, but ideal for their middle class and elite nationals.

  Due to buying power and low labor costs, foreign hospitals not only save on doctors' fees, but also keep expenses down with regards to
  their nursing staff, cleaning crews, and other general hospital upkeep expenses. All of which does not even begin to take into account the
  costs associated with the highly expensive litigious malpractice environment in most Western nations. Moreover without the cumbersome
  insurance and secondary distributor structures these facilities have more freedom in making economic decisions that enable affordable
  health care and high profit margins.

  Profiteering on the weak and hopeless has been present since the days of quack doctors selling elixirs and tonics from the back of their
  covered wagons. As the trend of medical tourism continues to expand, expect to read stories of patients who went to foreign medical
  facilities returning with botched procedures and other secondary complications. Most countries outside the U.S. do not have the same
  channels of legal recourse for malpractice lawsuits that are available here at home. This perceived threat alone will be the main detractor
  to full scale exoduses of American patients abroad.

  On the Horizon

  It is clear that medical device manufacturers and healthcare providers must now pay close attention to the healthcare industries of foreign
  countries to keep track of where American healthcare dollars are being spent.The primary target patients for medical tourism are the 45
  million uninsured Americans, in addition to the nearly 250 million insured Americans with generally limited coverage plans or those
  restricted due to pre-existing conditions.

  Furthermore, look for employers to offer benefits and incentives to their employees to manage their own healthcare costs with spending
  accounts allowing them more autonomy in selecting how they select their medical options. Companies like General Motors spend
  approximately $5.6 billion a year on health care alone for its employees, equating to nearly $1,525 of each car they produced. These high
  healthcare expenditures have led to low profitability and high costs and are a significant restrictor to company growth and profitability.
  Retiree health care costs have become a major competitive burden for many of America's largest corporations.

  Even some of the larger hospitals in the U.S. are partnering with hospitals abroad to fulfill tasks.A number of U.S. hospitals already use Indian
  doctors for night emergencies, sending data from X-rays and scans over the internet for instant analysis.

  Providers must also realize that is not also simply an issue of cost.Americans who are on waiting lists for procedures for 6 months or more,
  can often schedule a surgical procedure abroad and be on the table within two weeks for anything ranging from heart valve repair
  procedures to bone marrow transplants. A bone marrow transplant can cost close to $250,000 in the U.S. can be completed abroad for
  close to $69,000.

  In the distant future it is also plausible that experimental techniques or approaches such as embryonic stem cell treatment or bioengineering
  could be sought out in nations that tend to have more relaxed views on the ethics of stem cell therapy.

  Being able to recognize the global market and identify opportunities to optimize healthcare and costs in the U.S., rather than
  trying to resist or ignore the
  changing environment will be a dynamic new trend for industry participants to master. Due to active marketing on the parts

Learn more at:                                                        Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                This Week's Industry Focus:
                                                                                                                           Medical Devices

  of foreign hospitals and governments, U.S. employers offering incentives to reduce the burden of healthcare costs, the ease
  of information readily available on the internet, expanded international air travel routes to the nations mentioned, along with
  hotel and medical facility coordinated packaged discounts for travelers, medical tourism is a vibrant and growing industry
  that will significantly alter the dynamics that have governed the healthcare industry in the past.

                                     Cost Comparison of Medical Procedures Abroad vs US

                                Procedure                                        Cost USD ($)
                                                                  United States                         India
                   Bone Marrow Transplant                           250,000                            69,000
                   Liver Transplant                                 300,000                            69,000
                   Cardiac Surgery                                   30,000                            8,000
                   Orthopedic Surgery                                20,000                            6,000
                   Cataract Surgery                                   2,000                            1,250

                   Dental Procedures                                           Cost in USD ($)

                                                                  United States                         India
                   Smile designing                                    8,000                             1,000
                   Metal Free Bridge                                  5,500                              500
                   Dental Implants                                    3,500                              800
                   Porcelain Metal Bridge                             3,000                              300
                   Porcelain Metal Crown                              1,000                               80
                   Tooth impactions                                   2,000                              100
                   Root canal Treatment                               1,000                              100
                   Tooth whitening                                     800                               110
                   Tooth colored composite fillings                    500                                25
                   Tooth cleaning                                      300                                75


Learn more at:                                              Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                         This Week's Industry Focus:
                                                                                                                                    Medical Devices

  Company Spotlight: CoAxia, Inc
  CoAxia is dedicated to the development of next generation technology in the treatment of cerebral
  ischemia due to stroke or vasospasms. By enhancing blood flow through collateral circulation to the
  periphery of the stroke, their NeuroFlo device has the potential to limit the degree of neurological
  damage; and may be able to do so out to 24 hours. Most current forms of treatment are only effective
  out to a few hours.The NeuroFlo Device has the potential to not only increase the safety and efficacy
  of stroke treatment, but also greatly expand the treatment time window.

  Founded in 1999 and located in Maple Grove, MN CoAxia, Inc was based on the clinical observations of Dr. Denise Barbut, who after making
  observations during Coronary Artery Bypass Graft (CABG) surgeries, conceived of a unique way to increase cerebral blood flow. Company
  CEO Andrew Weiss has degrees from MIT and Columbia, and years of industry experience serving General Electric Medical Systems, was
  President and CEO of Applied Biometrics, and most recently VP/GM Neurological Division among other positions at Medtronic, Inc.

  Key Technology or Flagship Product:

  CoAxia's NeuroFlo perfusion augmentation therapy is delivered via a unique dual balloon catheter that partially occludes the descending
  aorta and is thereby able to divert additional blood flow into the brain and limit the damage of a stroke or other life threatening
  neurovascular event. Stroke is the leading cause of brain damage resulting in disability in the U.S. By increasing blood flow to the brain, this
  device has the potential to significantly reduce the extent of brain damage. Similar in theory to when the body redirects blood flow to
  protect its vital organs in case of hypothermia, the NeuroFlo device performs that role in protecting the brain by increasing the flow of
  oxygen-rich blood; thereby limiting the risk and extent of complications stemming from brain damage. In fact, due to its unprecedented
  capabilities this groundbreaking system was one of the select recipients of the U.S. Food and Drug Administration Center for Devices and
  Radiological Health (CDRH) 2005 Innovation Award.

  Noteworthy Milestones:

  1999:    Founded by Denise Barbut M.D
  2003:    Completed human feasibility work
  2004:    $17.6 million in Series B funding Co-led by Canaan Venture Partners and Prism Venture Partners and included Affinity Capital, Baird
           Venture Partners and Johnson & Johnson Development Corporation.
  2005:    FDA Humanitarian Device Exemption (HDE) approval of NeuroFlo device for cerebral vasospasm in March.
  2005:    FDA approval of pivotal stroke Investigational Device Exemption (IDE) for NeuroFlo device in June.
  2005:    First stroke trial patient enrolled in October
  2006:    Currently more than 30 sites participating in stroke trial with ongoing enrollment.

  Contact Information
  CoAxia, Inc.
  Rick Schallhorn
  Vice President, Marketing and Business Development                                  Did you know ?
  10900 73rd Avenue North, Suite 102                                                  Currently Only 5% of stroke victims
  Maple Grove, MN 55369                                                               receive timely and effective acute
  Phone: 763-315-1809                                                                 treatment.
  Fax: 763-315-3660

Learn more at:                                                       Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                            This Week's Industry Focus:
                                                                                                                                       Medical Devices

  Reimbursement & Regulatory News
  Recent FDA Approval Announcements:
     Date     Company                                Device Name         Function                                                   Designation
              T riPa th Ima g ing Inc . &
              Ve nta na Me d ic a l                Ventana Image         Quantitative imaging tissue analysis of Ki-67
    17-Apr                                                                                                             510(K) Clearance
              Sy s te ms , Inc .                   Analysis System       biomarker for prognosis of cancer
              (Burling to n, N .C. )
              Bo s to n Sc ie ntific               Precision(TM)
                                                                         Electrostimulation of the occipital nerve to           Initiation of clinical
    17-Apr    Co rp o ra tio n (N a tic k ,        neurostimulation
                                                                         alleviate treatment resistive migranes                 trial
              Ma s s )                             system
                                                                         Generic equivalent of Merck
              My la n La b o ra to rie s Inc .     Finasteride
    18-Apr                                                               Pharmaceuticals Proscar(TM) benign                     Tentative Approval
              (Ca nno ns b urg , PA)               Tablets USP
                                                                         prostate hyperplasia treatment
                                                   AVIVA premium
              Ba xte r H e a lthc a re
                                                   line of          IV solutions packaged in a PVC, latex and
    18-Apr    Co rp o ra tio n ( D e e rfie ld ,                                                                                Full approval
                                                   intravenous      DEHP free fluid pathway
              T he ra Que s t                      Tramadol
                                                                                                                                Fast Track
    18-Apr    Bio s c ie nc e s (BLU E             Extended Release Treatment for HIV-associated neuropathy
              BELL, Pa )                           (ER)
                                                                    Thrombin receptor antagonist for prevention
                                                                    of arterial thrombosis in patients with acute
              Sc he ring -P lo ug h                                                                                             Fast Track
    19-Apr                                         SCH 530348       coronary syndrome, peripheral arterial
              Ke milwo rth, N .J )                                                                                              designation
                                                                    disease, or with previous incedence of
                                                                    myocardial infarction or stroke
              N o v a rtis
                                                                                                                                Submitted New
              Pha rma c e utic a ls                                      Renin inhibitor treatment for high blood
    20-Apr                                         Rasilez (aliskiren)                                                          Drug Application
              Co rp o ra tio n (Ea s t                                   pressure
              H a no v e r, N .J .)
              H o ffma nn-L a R o c he Inc .                             Treatment for renal anemia associated with             Biological License
    20-Apr                                         C.E.R.A
              (N utle y , N .J .)                                        chronic kidney disease                                 Application (BLA
              R o c k we ll Me d ic a l            Soluble Ferric
                                                                         Iron replacement via dialysate during                  Submission of pre-
    20-Apr    T e c hno lo g ie s , Inc .          Pyrophosphate
                                                                         hemodialysis                                           IND package
              (W ixo m, Mic h)                     (SFP

  Recent Centers for Medicare & Medicaid Services Coverage Announcements:

  Thursday, March 23, 2006
  The Centers for Medicare & Medicaid Services announced it will expand coverage of cardiac rehabilitation services including medical
  evaluation, education, and nutrition services to patients who have had heart valve repair or replacement, percutaneous transluminal coronary
  angioplasty (PTCA) or coronary stenting, or a heart or combined heart-lung transplant.

  Wednesday, March 22, 2006
  The Centers for Medicare & Medicaid Services announced it will cover microvolt T-wave alternans (MTWA) diagnostic testing for Medicare
  beneficiaries. Testing will provide physicians another tool to help to identify patients who are at risk from sudden cardiac death from life-
  threatening irregular heartbeats.

Learn more at:                                                          Call Toll Free: 877.GOFROST (877.463.7678) or Email:
                                                                                                                              The Healthcare Group

The Frost & Sullivan Healthcare Group specializes in closely monitoring the healthcare marketplace to provide critical information,
opportunities, and strategic recommendations for market participants. Our global team of highly skilled industry analysts and consultants are
educated and experienced in a variety of healthcare market sectors, and maintain well-developed, long-standing relationships with key industry
participants. Leveraging these assets, the team provides clients with comprehensive industry knowledge, including detailed coverage of market,
technology, economic, and customer-focused trends and forecasts.

The Frost & Sullivan Healthcare team offers extensive coverage of the following markets and sectors:

  Drug Discovery                                                           Medical Devices
  • Proteomics                         •   SNP                             • Cardiovascular Devices                • General Medical Devices
  • Protein Markets                    •   Pharmacogenomics                • Orthopedic Devices                    • Hospital Supplies and
  • DNA & Protein Microarrays          •   Mass Spectromerty               • Home Care                               Products
  • Research Consumables               •   Gel Electrophoresis             • Surgical and Infection Control        • Wound Care/ Management
  • High Throughput Screening          •   Laboratory Information            Products                                Products
  • Bioinformatics                          Systems

  Clinical Diagnostics                                                      Medical Imaging
  • Molecular Diagnostics               • Genetic Testing                   • Core Imaging Modalities              • PACS & Imaging IT
  • Immuno-chemistry                    • Infectious Disease                • Imaging Agents                       • Digital Imaging
  • Point-of-Care                         Diagnostics                       • Imaging Software
  • Cell Culture                        • Cancer Diagnostics
  • In Vitro Diagnostics

  Pharmaceuticals & Biotechnology                                           Patient Monitoring
  • Oncology                                                                • Cardiac Monitoring                   • Temperature Monitoring
  • Drug Delivery               • Contract Research                         • External Defibrillators              • Pulse Oximetry
  • Biotechnology               • Ophthalmics                               • Multi-Parameter Monitoring           • Remote Patient Monitoring
  • CNS                         • Chronic Diseases                          • Glucose Monitoring                   • Patient Monitoring IT
  • Contract Manufacturing                                                  • Blood Pressure Monitoring            • Sleep Apnea Monitoring

 Healthcare & Life Sciences IT
 • Electronic medical records                    • Acute Care Information Systems                • Claims management through IT
 • Data and storage management                   • CPOE                                          • RFID in Healthcare
 • Emerging wireless technologies                • Enterprise clinical information systems       • RHIOs


  Growth Consulting - Clients may leverage our unique                       Customer Research - Clients gain insights into their
  combination of market expertise, global presence, and relationships       customers behaviors and attitudes, find out what end users think
  with key industry players for customized research, business               of their company, and how their products should look and feel in
  strategy, consumer analysis, and organizational development               the future. These analyses are designed to assist you in
  projects. Clients get powerful and practical solutions to address         formulating and applying effective product marketing strategies
  their unique challenges and develop winning strategies for growth.        across your product and service lines.

  Monali Patel                       Ryan Goulding                        Stephen Mohan                          Greg Caressi
  Director, Healthcare Research      VP, Healthcare Consulting            VP, Healthcare Sales                   VP, Healthcare & Life Sciences
  t) 650.475.4506                    t) 650.475.4508                      t) 210.348.1032                        t) 650.475.4555
  e)                e)               e)             e)

Learn more at:                                                      Call Toll Free: 877.GOFROST (877.463.7678) or Email:

To top